🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

MICRO: a Registry Study in Patients With Microvascular Angina

Recruitingn/aAges 18 Years - 85 YearsAllJohannes Gutenberg University Mainz
NCT04612322 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The evidence above demonstrates that microvascular dysfunction is an important determinant of patient prognosis, which however remains poorly classified. Given the high burden of disease and the severity of the functional impairment in these patients, the lack of a clear definition for this disease has a potentially large clinical importance. It is important to better describe the phenotype of these patients, identify the predictors of prognosis, and determine the impact of diagnosis.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 18 and \<85 years. * Chronic coronary syndrome (including patients with anginal equivalents) * Angina CCS class II-IV * Evidence of reversible ischemia on non-invasive testing * Availability of the following measurements: 1. Index of microvascular resistances (IMR), 2. Resting full-cycle ratio (RFR), 3. Fractional flow reserve (FFR), 4. Coronary flow reserve (CFR) * Willingness to participate and ability to understand read and signed the informed consent document before the procedure Exclusion Criteria: At least one of the following: * Pregnancy and or lactation. * Medical or psychological conditions that would jeopardize an adequate and orderly participation. * Left ventricular ejection fraction lower than 30% * Previous coronary artery bypass surgery (CABG) to all major branches in the LAD and left circumflex (LCX) territory, such that IMR cannot be measured * Decompensated congestive heart failure (CHF) * Chronic or acute renal failure with creatinine \>2mg/dl * Severe valvular heart disease * Patients with comorbidities limiting life expectancy to less than one year
💊

What it tests

  • Assessment of microvascular function with intracoronary hemodilution
📍

Where

1 site
Universitätsmedizin Mainz
Mainz, Germany
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy